Just because you are employed doesn’t mean that you will have the luxury of health insurance. Despite the fact that states mandate specific insurance requirements based on the number of employees in the company, statistics show a different story. In 2016 alone, 27.6 million people did not have health coverage. Of those individuals, 75% of them had at least one full-time ... Continue Reading
Penguin Pay Breakthrough! Loans for Prescription Drugs
Introducing Penguin Pay, a feature exclusive to SingleCare. We are often told to save up for the unexpected. But often, needing to fill a costly prescription is outside of our budget, our plans and what we can reasonably afford. There you are, saving up for [one hundred other daily essentials] when you get hit with a prescription drug cost that's several hundred dollars (or ... Continue Reading
Erleada, A New Prostate Cancer Treatment
As of February 2018, the FDA approved Erleada (also known by its generic name of apalutamide) a new drug for the treatment of certain types of prostate cancer. While there are many drugs available to treat prostate cancer, this is the first that the FDA has approved for hormone-resistant non-spreading (castration-resistant non-metastatic) tumors. The approval is welcome news ... Continue Reading
FDA Approves Biktarvy for Use in HIV Regimens
In January 2018, the Federal Drug Administration (FDA) approved the use of Biktarvy for the treatment of HIV infections in adults. Biktarvy (or any other current HIV medicine) cannot cure an HIV infection, nor prevent HIV from developing into AIDS. However, an HIV regimen (a combination of HIV medicines) can help HIV-infected people live longer, and reduce the possibility of ... Continue Reading
FDA Approves Symdeko for Treatment of Cystic Fibrosis
Symdeko was approved by the FDA in February 2018, for the treatment of certain types of cystic fibrosis, in patients aged 12 years or older. According to Vertex Pharmaceuticals, cystic fibrosis is estimated to affect 75,000 people across North America, Europe, and Australia. Jeffrey Leiden, M.D., Ph.D., president of Vertex (the company behind the drug), says Symdeko’s ... Continue Reading